Viatris biosimilars deal gives lift to Biocon’s global aspirations

$3.3B deal with Mylan-Upjohn offshoot gives Indian biotech leader pipeline of 20 biosimilars and over $1B in revenue

March 1, 2022 2:21 AM UTC

India’s Biocon is expanding its biosimilars business to the world’s largest pharmaceutical markets via its $3.4 billion acquisition of partner Viatris’ biosimilars unit.

The Biocon Biologics Ltd. unit of Biocon Ltd. (NSE:BIOCON; BSE:532523) said Monday that it will acquire the biosimilars business of Viatris Inc. (NASDAQ:VTRS) for about $3.3 billion in a cash and stock deal...

BCIQ Company Profiles

Biocon Ltd.

Viatris Inc.